Publications

Aldridge BB, Barros-Aguirre D, Barry CE, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu X-J, Cooper CB, Dartois V et al..  2021.  The Tuberculosis Drug Accelerator at year 10: what have we learned? Nat Med. 27(8):1333-1337.

Maksymiuk C, Ioerger T, Balakrishnan A, Bryk R, Rhee K, Sacchettini J, Nathan C.  2015.  Comparison of transposon and deletion mutants in Mycobacterium tuberculosis: The case of rv1248c, encoding 2-hydroxy-3-oxoadipate synthase.. Tuberculosis (Edinb). 95(6):689-694.

Patel SJ, Oliveira AP, Zhou JJulia, Alba L, E Furuya Y, Weisenberg SA, Jia H, Clock SA, Kubin CJ, Jenkins SG et al..  2014.  Risk factors and outcomes of infections caused by extremely drug-resistant gram-negative bacilli in patients hospitalized in intensive care units.. Am J Infect Control. 42(6):626-31.

Rhee KY, Gardiner DF, Charles M.  2005.  Decreasing in vitro susceptibility of clinical Staphylococcus aureus isolates to vancomycin at the New York Hospital: quantitative testing redux.. Clin Infect Dis. 40(11):1705-6.